Effects of intranasal oxytocin on threat- and reward-related functional connectivity in men and women with and without childhood abuse-related PTSD

Psychiatry Res Neuroimaging. 2021 Nov 30:317:111368. doi: 10.1016/j.pscychresns.2021.111368. Epub 2021 Aug 20.

Abstract

Novel treatments that target neurobiological alterations associated with childhood trauma, particularly among those with posttraumatic stress disorder (PTSD), could mitigate negative outcomes for these at-risk individuals. PTSD is characterized by abnormalities within the brain's salience network and reward circuitry, which are modulated by intranasal oxytocin. Using a double-blind, randomized, placebo-controlled crossover design, we tested whether intranasal oxytocin (24 international units) influenced functional coupling of the amygdala with the anterior insula (AI), dorsal anterior cingulate cortex, and nucleus accumbens in response to implicitly presented fearful, angry, and happy faces among childhood trauma-exposed individuals with (n = 16, 9 women) and without PTSD (n = 18, 12 women). Psychophysiological interaction analyses revealed that oxytocin effects were limited to amygdala-AI connectivity in the fear condition, distinct for men and women, and not impacted by PTSD diagnosis. In response to fear faces, oxytocin reduced left amygdala-left AI connectivity for women but not men; reduced left amygdala-right AI connectivity among women, but increased this connectivity in men; and reduced right amygdala-right anterior insula connectivity for men, but increased it for women. Results suggest that intranasal oxytocin modulates threat salience among childhood trauma-exposed individuals and that these effects vary as a function of gender and hemisphere.

Trial registration: ClinicalTrials.gov NCT01963078.

Keywords: Anger; Emotion; Facial affect; Fear; Happiness; Psychophysiological interaction; Trauma; fMRI.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Intranasal
  • Adverse Childhood Experiences
  • Female
  • Humans
  • Male
  • Oxytocin* / administration & dosage
  • Oxytocin* / pharmacology
  • Reward
  • Stress Disorders, Post-Traumatic* / drug therapy

Substances

  • Oxytocin

Associated data

  • ClinicalTrials.gov/NCT01963078